Big News, page-19

For sure there are bigger markets and users who can pay $10/test rather than $1. However, the developing world opportunity isn't a drop in the bucket in monetary terms (not to mention the humanitarian benefits). Say RAP can reach 50% of the 151M cases of pneumonia each year @ $1/test...that's 75M in revenue right there. I used it as an example to justify the current share price and because it was the original driver for big Bill and Melinda's investment. RAP has already announced that it is collaborating with a global leading humanitarian organisation, surely more news will follow there. Anyway, the share price will not go up in a straight line, but we're not in a bubble. If you want to see a bubble...look at the lithium wannabees.